Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
about
Chronic myeloid leukemia: reminiscences and dreamsTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.Best Practices in Chronic Myeloid Leukemia Monitoring and ManagementTargeting EZH2 for cancer therapy: progress and perspective.Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points.Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Chronic myeloid leukemia: Second-line drugs of choice.The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Bosutinib for Chronic Myeloid Leukemia.Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibPhase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.Bosutinib in chronic myeloid leukemia: patient selection and perspectives.Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.
P2860
Q26748769-8B199366-CB99-4D86-8CED-30FC5D949E1AQ30242015-065D9AFF-7769-4BAB-ADAB-4007A04A457AQ33434675-817743CE-8D8D-4EAC-A906-91E125D7CBE8Q33442587-4D78CA7D-2E0B-40EF-B97D-3E2770067B9EQ36140620-0AA0BFAF-53AF-44EA-A01B-3F7BD2142768Q36533121-DA727D06-EE02-4010-B474-CC9F6458B018Q36884361-9B26CBD8-E460-4C48-8406-080599929D27Q37204063-4CEA4AA0-9150-433A-B32E-014E5FFD34FDQ37461942-4CD75137-4004-4BC5-98B8-0539D5236050Q37579983-76085DC5-D7B6-4DCA-80FC-B32A7ACCFE91Q38254385-8A84D975-9F33-4F83-9A75-36AD7452A075Q38392673-85B6AB11-48F4-4002-BD94-BF9C674C5CBFQ38457554-FBBD97BA-1FE1-49FB-AF40-6CD0903C62A1Q38640422-BB0B7C12-055D-4B04-BEA3-FA4D911CB860Q38642952-CDABF0F2-0CD2-4E76-9C6D-9C5330799838Q38672008-70B2B543-AE3E-4B84-836B-E74E5A5140EFQ38707841-814FE3A3-F417-4FC0-804C-9B04666AFA2FQ38835127-44B45213-28A3-4C73-B385-EDB53B940771Q38937497-150E157F-4E27-4F5E-A01B-D554189B4810Q39310587-9A974E4F-1CEF-4D97-A00A-076C63EA5B84Q40302552-9A817091-D035-4F76-B734-8E4558C1BF00Q41304682-4D98BB45-6899-4A27-A41F-1F80B91302A8Q42874199-8EAB4F9C-85C9-4758-B777-1EF07C4941E2Q46220838-AF00CC32-18CD-495D-9A0E-7C3C06357C9AQ47211218-878CA1D5-A6C8-4604-BC00-2F2BF24C8E7AQ48124245-5B2221A2-F459-45D9-B3A0-3AE5EE2BFF47Q48253155-90C5342A-BEC0-4F3A-9D5C-54468670898FQ48275281-92AC6A4A-E36B-4FEC-8095-596E6E424CE7Q48778777-6D3C7DA3-621F-4B95-A32D-4C73611AE816Q49553324-18B66BA4-F579-4FA5-BB02-BEC0DA3D8FC9Q50068063-C7CA2F2D-B2A0-4EF2-B846-E81A308427A9Q51415497-43C856C7-7C5F-44E6-AFB5-BFDA504E29FFQ52562694-C82A4C9B-0CAB-4A18-9ADD-FD294316E4BFQ52571134-FDDBF6F6-5C58-4D27-AE84-33C41B844DF1Q52641875-92291E7E-5D36-4007-8CF0-5CDA75A83631Q52816089-A828BDCB-D79E-44A9-8240-2979060E0A6AQ53129924-DB238264-808D-40D6-A8B9-E0FE567ACCC8Q54109036-6ECE5414-0F4A-4AAA-B291-F9CE9C98A1B7
P2860
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Bosutinib efficacy and safety ...... e: Minimum 24-month follow-up.
@ast
Bosutinib efficacy and safety ...... e: Minimum 24-month follow-up.
@en
type
label
Bosutinib efficacy and safety ...... e: Minimum 24-month follow-up.
@ast
Bosutinib efficacy and safety ...... e: Minimum 24-month follow-up.
@en
prefLabel
Bosutinib efficacy and safety ...... e: Minimum 24-month follow-up.
@ast
Bosutinib efficacy and safety ...... e: Minimum 24-month follow-up.
@en
P2093
P2860
P50
P356
P1476
Bosutinib efficacy and safety ...... e: Minimum 24-month follow-up.
@en
P2093
Andrey Zaritskey
Dong-Wook Kim
Edo Vellenga
Francisco Cervantes
H Jean Khoury
Kathleen Turnbull
Nadine Besson
Ricardo Pasquini
P2860
P304
P356
10.1002/AJH.23728
P577
2014-04-28T00:00:00Z